ClinicalTrials.gg
Not yet recruitingNCT07730671PENSA+Updated Jul 28, 2026

PENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers

An observational study in Subjective Cognitive Decline (SCD), sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation. Not yet recruiting at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
121
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation — 5 open to participants now, 7 under way, none of them phase 3. Alzheimer Disease · Barcelonabeta Brain Research Center, Pasqual Maragall Foundation.

Started
2026
with 2 others
Observational
9 of 15
4 open now
Registered
15th of 15
by date

Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, this one is one of 3 that started in 2026, is one of 9 observational ones, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

5 of the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, or all of them as a file.
02

Study summary

PENSA+ is a 5-year follow-up study of participants who previously completed the PENSA clinical trial (NCT03978052), which evaluated an intensive multimodal lifestyle intervention, with or without epigallocatechin gallate (EGCG), in APOE-ε4 carriers with subjective cognitive decline, a population at increased risk of developing Alzheimer's disease.

The purpose of this study is to determine whether the cognitive, biological, and lifestyle benefits observed after the original intervention are maintained over the long term. Researchers will evaluate cognitive performance, the incidence of mild cognitive impairment, dementia risk, brain imaging, blood biomarkers, physical fitness, lifestyle behaviors, and psychosocial factors approximately five years after completion of the intervention.

The study will also investigate the biological and behavioral mechanisms associated with sustained cognitive benefit, identify participant characteristics associated with better long-term outcomes, evaluate the long-term cost-effectiveness of the intervention using healthcare utilization data, and explore whether lifestyle changes have influenced participants' study partners. No new intervention will be administered as part of this follow-up study.

Read the detailed description

Alzheimer's disease (AD) is the leading cause of dementia and is characterized by a long preclinical phase during which pathological changes accumulate before the onset of clinical symptoms. This extended asymptomatic period provides an opportunity to implement preventive strategies aimed at delaying or reducing cognitive decline. Multidomain lifestyle interventions targeting modifiable risk factors have emerged as one of the most promising approaches for dementia prevention, demonstrating beneficial effects on cognitive performance and overall brain health, particularly in individuals at increased risk of developing AD. However, the long-term durability of these effects, the biological mechanisms underlying sustained benefit, the characteristics of individuals most likely to respond, and the long-term economic value of these interventions remain incompletely understood.

The PENSA+ study is a long-term follow-up of the PENSA randomized clinical trial (NCT03978052), which evaluated an intensive personalized multimodal lifestyle intervention in cognitively unimpaired APOE-ε4 carriers with subjective cognitive decline. The intervention combined dietary counseling, physical exercise, cognitive training, psychoeducation, social stimulation, and vascular risk management, and was administered with either epigallocatechin gallate (EGCG)-a naturally occurring green tea polyphenol with antioxidant, anti-inflammatory, metabolic, vascular, and potential neuroprotective properties-or placebo. Participants assigned to the control group received general healthy lifestyle recommendations. The original trial demonstrated improvements in cognitive performance, lifestyle behaviors, physical fitness, cardiometabolic health, and dementia risk in the intervention groups, with cognitive and lifestyle benefits persisting beyond the active intervention period. However, whether these benefits are maintained over the longer term and the mechanisms responsible for their persistence remain unknown.

The primary objective of PENSA+ is to evaluate cognitive performance, the incidence of mild cognitive impairment, and dementia risk approximately five years after completion of the original intervention. Secondary objectives are to investigate the biological, behavioral, and psychosocial mechanisms associated with sustained cognitive benefit, identify long-term responder phenotypes, and evaluate the long-term cost-effectiveness and cost-utility of the intervention. Exploratory objectives include assessing long-term clinical outcomes and healthcare resource utilization through electronic health records for up to 10 years after the intervention and evaluating potential spillover effects on participants' study partners.

Participants who completed the original PENSA trial will undergo comprehensive follow-up evaluations, including cognitive, neurological, neuroimaging, biomarker, physical fitness, lifestyle, and psychosocial assessments. Data collected during the original trial will be integrated with the five-year follow-up data to characterize long-term cognitive trajectories, identify determinants of sustained cognitive resilience, and provide evidence on the long-term clinical and economic impact of intensive multidomain lifestyle interventions for Alzheimer's disease prevention.

03

Conditions studied

  • Subjective Cognitive Decline (SCD)

Browse trials for

Keywords

  • Alzheimer's Disease
  • Dementia Prevention
  • Subjective Cognitive Decline
  • APOE-ε4 carriers
  • Multidomain Lifestyle Intervention
  • Epigallocatechin Gallate (EGCG)
  • Brain Health
  • Blood Biomarkers
  • Long-Term Follow-up
  • Subjective Cognitive Decline (SCD)
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals who previously completed the PENSA study will constitute the target population of this study.

Of the 129 participants initially enrolled in the PENSA study, 121 completed it.

Participants who completed the PENSA study were allocated as follows:

  • 47 participants in the MLI+EGCG group
  • 49 participants in the MLI+placebo group
  • 25 participants in the CG

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Any individual who has completed the PENSA study, does not meet any exclusion criteria, and provides consent is eligible to participate in this study.

Exclusion criteria

Exclusion Criteria

Participants will be excluded from the study if they meet any of the following conditions:

  • A prior clinical diagnosis of dementia, regardless of etiology.
  • Current institutionalization (e.g., residence in nursing homes, long-term care facilities, or similar institutions).
  • Impaired decision-making capacity, defined as the inability to provide independently due to cognitive, legal, or medical reasons (e.g., loss of autonomy or requirement of a legal representative).
  • Current participation in another interventional clinical trial, or participation in an interventional clinical trial within the previous 3 months prior to baseline; unless deemed by the investigator not to interfere with PENSA+ procedures or outcomes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
121 participants (estimated)
Patient registry
No

Groups and cohorts

  • Multimodal Lifestyle Intervention + EGCG

    Participants who completed the original PENSA trial and were assigned to the intensive personalized multimodal lifestyle intervention combined with epigallocatechin gallate (EGCG) supplementation for 12 months. The intervention included dietary counseling, physical exercise, cognitive training, psychoeducation, social stimulation, and vascular risk management. Participants are followed approximately 5 years after completion of the intervention (current PENSA+ study) to evaluate long-term cognitive, biological, lifestyle, and health outcomes.

  • Multimodal Lifestyle Intervention + Placebo

    Participants who completed the original PENSA trial and were assigned to the intensive personalized multimodal lifestyle intervention combined with placebo supplementation for 12 months. The intervention included dietary counseling, physical exercise, cognitive training, psychoeducation, social stimulation, and vascular risk management. Participants are followed approximately 5 years after completion of the intervention (current PENSA+ study) to evaluate long-term cognitive, biological, lifestyle, and health outcomes.

  • Control

    Participants who completed the original PENSA trial and were assigned to the control group, receiving general healthy lifestyle recommendations without the intensive multimodal intervention. Participants are followed approximately 5 years after completion of the original study (current PENSA+ study) to evaluate long-term cognitive, biological, lifestyle, and health outcomes.

06

What researchers measure

Primary outcomes

  1. Global Cognitive Performance (PACC-exe Composite Score)

    Global cognitive performance assessed using the Preclinical Alzheimer Cognitive Composite for executive function, a composite score derived from six neuropsychological tests: Montreal Cognitive Assessment (score 0-30, higher scores indicate better cognition), Free and Cued Selective Reminding Test (score 0-48, higher scores indicate better episodic memory), Logical Memory Delayed Recall from the Wechsler Memory Scale (score 0-48, higher scores indicate better delayed verbal memory), WAIS-IV Coding (higher scores indicate better processing speed), Stroop Color-Word Test Interference score (higher scores indicate better inhibitory control and executive function), and Five Digit Test (higher scores indicate better executive functioning and cognitive flexibility). Individual test scores are converted to standardized z-scores based on the baseline mean and standard deviation of the study cohort, and the PACC-exe score is calculated as the arithmetic mean of these z-scores.

    Time frame: Baseline, 12 months, and approximately 5 years after completion of the original PENSA intervention

  2. Incidence of Mild Cognitive Impairment (MCI)

    Incidence of Mild Cognitive Impairment determined according to clinical diagnostic criteria based on neuropsychological evaluation and clinical assessment performed at the 5-year follow-up visit. Diagnosis will require: (1) evidence of objective cognitive impairment on standardized neuropsychological assessment; (2) reported cognitive decline from previous functioning by the participant, an informant, or documented longitudinal assessment; (3) preserved independence in activities of daily living (impaired performance will be defined as below the 10th percentile, scaled score \<7, or ≥1.3 SD below age- and education-adjusted normative means); and (4) absence of dementia. Domain-specific impairment will be defined as low performance in ≥3 of 5 memory measures, ≥3 of 5 executive function measures, or ≥2 of 2 language measures. Final diagnosis will be established by a neurologist based on the integrated evaluation of neuropsychological, clinical, functional, and behavioral information.

    Time frame: Approximately 5 years after completion of the original PENSA intervention

  3. Dementia Risk (LIBRA Index)

    Dementia risk assessed using the Lifestyle for Brain Health (LIBRA) Index, a weighted composite score of modifiable risk and protective factors for dementia. Lower scores indicate lower estimated dementia risk. The dementia risk assessed with the LIBRA Index is a weighted composite score of 12 modifiable risk and protective factors for dementia. These modifiable risks are the following: 1. Coronary heart disease 2. Chronic kidney disease 3. Hypertension 4. Hypercholesterolemia 5. Diabetes 6. Depression 7. High cognitive activity 8. Obesity 9. Low/moderate alcohol use 10. Physical inactivity 11. Smoking 12. Healthy diet

    Time frame: Baseline, 12 months, and approximately 5 years after completion of the original PENSA intervention

Secondary outcomes

  1. Longitudinal changes in memory and executive function

    Longitudinal changes in cognitive domains (memory and executive function scores, PMCID: PMC12413734).

    Time frame: Baseline, 12-month, 5-year

  2. Longitudinal changes in Mediterranean diet adherence

    Diet will be assessed through Mediterranean Diet Adherence Screener (MEDAS-14). The MEDAS-14 is a 14-item questionnaire for the assessment of Mediterranean diet compliance. It has been developed and validated by researchers of the PREDIMED study (PMCID: PMC8710807). The maximum possible score is 14 points. This questionnaire allows the participants to be classified according to their adherence to the Mediterranean diet, being appropriate if the score is ≥10 or not appropriate if the score is \<10.

    Time frame: Baseline, 12-month, 5-year

  3. Longitudinal changes in physical activity

    Physical activity is measure through the Short Minnesota Leisure Time Activities Questionnaire (VREM). The VREM questionnaire asks for information on six activities carried out in the last month (or usual month) in order to find out the level of PA performed: walking, gardening in the garden, doing sport or dancing, climbing stairs, shopping on foot, and cleaning the house. cleaning the house (PMID: 23223762). According to the number of minutes spent on each activity and the frequency they are carried out over the course of a year, the energy expenditure is estimated for 14 days, expressed in Metabolic Equivalents (METs) per minute per 14 days (MET-min-14 days). The VREM makes it possible to distinguish between very active (more than 5,000 MET-min-14 days), active (between 3,000 and 4,999), moderately active (between 1,250 and 2,999), and sedentary (less than 1,250).

    Time frame: Baseline, 12-month, 5-year

  4. Longitudinal changes in quality of life

    Quality of life is measured through the World Health Organization Quality of Life (WHOQOL)-BREF. The WHOQOL-BREF comprises 26 items, categorized into four domains: physical health (7 items), psychological well-being (6 items), social connections (3 items), and environmental health (8 items) (PMID: 15085902). Additionally, it includes items addressing the overall quality of life and general health. Each item in the WHOQOL-BREF is assessed on a five-point ordinal scale. These scores are then linearly transformed to a 0-100 scale. The physical health domain encompasses aspects such as mobility, daily activities, functional capacity, energy, pain, and sleep. Within the psychological domain, assessments cover self-image, negative thoughts, positive attitudes, self-esteem, mentality, learning ability, memory concentration, religion, and mental status. The social relationships domain explores personal relationships, social support, and aspects of one's sex life.

    Time frame: Baseline, 12-month, 5-year

  5. Longitudinal changes in physical fitness - Senior Fitness Test

    Physical fitness will be assessed using the Senior Fitness Test (SFT), a standardized battery that evaluates overall physical fitness in older adults, including muscle strength, aerobic endurance, flexibility, agility, and dynamic balance. Higher scores in the SFT indicate better physical fitness.

    Time frame: Baseline, 12-month, 5-year

  6. Longitudinal changes in physical fitness - Grip Strength Test

    Physical Fitness will be assessed with the Grip Strength Test. For this test, the best result from 3 trials for each hand will be recorded and summed.

    Time frame: Baseline, 12-month, 5-year

  7. Longitudinal Changes in Plasma Alzheimer's Disease Biomarkers and Neuroimaging Measures

    Change and trajectory in plasma AD biomarkers and neuroimaging measures of brain structure and function. Specifically, plasma AD biomarkers include the concentration levels of phosphorylated tau (p-tau217 and p-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), all expressed in pg/mL, as well as the amyloid-β 42/40 ratio. Simultaneously, neuroimaging markers derived from structural MRI include hippocampal, lateral ventricular volumes, and White Matter Hyperintensities (WMH) - all normalized to total intracranial volume (TIV)-, and a composite measure of cortical thickness in "AD-signature" regions (PMID: 21490323).

    Time frame: Baseline, 12-month, 5-year

  8. Economic Outcomes: Long-term Cost-Effectiveness and Cost-Utility

    Incremental cost-effectiveness ratios (ICERs) expressed as cost per unit improvement in global cognitive performance (PACC-exe), and the Incremental Cost-Utility Ratio (ICUR), expressed as the cost per Quality-Adjusted Life Year (QALY) gained based on EQ-5D-5L data.

    Time frame: Baseline, 12 months, and approximately 5 years after completion of the original PENSA intervention

Other outcomes

  1. Longer-term Clinical Outcomes and Healthcare Utilization Using EHRs (up to 10 years of follow-up)

    Incidence of all-cause dementia and AD identified via validated Electronic Health Record (EHR) algorithms. Time-to-event methods will be used where feasible to analyze longer-term incidence outcomes. Kaplan-Meier curves and Cox proportional hazards models, or alternative parametric/survival models if proportional hazards assumptions are not met, will be used to compare intervention groups with adjustment for baseline covariates. If event dates are not sufficiently precise or follow-up intervals are irregular, discrete-time survival models or regression models for cumulative incidence may be used instead. Longer-term healthcare utilization will be summarized descriptively and analyzed using count models (e.g., Poisson or negative binomial regression) or generalized estimating equations, as appropriate to the distribution of the data.

    Time frame: Baseline and within 10 years forward based on EHR

  2. Spillover Effect on study partners - Mediterranean diet adherence

    Concordance between participants and their study partners regarding Mediterranean diet adherence, measured through the Mediterranean Diet Adherence Screener (MEDAS-14).

    Time frame: Approximately 5 years after termination of PENSA

  3. Spillover effect on study partners - physical activity levels

    Concordance between participants and their study partners regarding physical activity adherence, measured through the Short Minnesota Leisure Time Activities Questionnaire (VREM).

    Time frame: Approximately 5 years after termination of PENSA

  4. Spillover Effect on study partners - cognitive engagement

    Concordance between participants and their study partners regarding cognitive engagement, which is measured through the Lifestyle Activities Questionnaire (LAQ). Cognitive and social activity will be measured using a questionnaire that results from the translation and adaptation of the LAQ. The LAQ is used to assess a participant's engagement in various daily activities with different cognitive demands, such as reading, playing musical instruments, or attending social gatherings. This questionnaire allows the quantification of both the frequency and the variety of these activities. A greater variety of participation in activities, as assessed by LAQ, was associated with reduced cognitive impairment (PMCID: PMC3508669).

    Time frame: Approximately 5 years after termination of PENSA.

07

Study locations

1 site
  • Fundació Pasqual Maragall
    Barcelona, Catalonia 08005, Spain
    • Anna Soteras Prat · Contactasoteras@barcelonabeta.org · +34 933 26 31 90
    • Natàlia Soldevila Domènech, MPH, PhD · Principal investigator
    • Oriol Grau-Rivera, MD, PhD · Sub investigator
    • Gonzalo Sánchez Benavides, PhD · Sub investigator
    • Ana Fernández Arcos, MD, PhD · Sub investigator
08

References and documents

Publications

  • Carlson MC, Parisi JM, Xia J, Xue QL, Rebok GW, Bandeen-Roche K, Fried LP. Lifestyle activities and memory: variety may be the spice of life. The women's health and aging study II. J Int Neuropsychol Soc. 2012 Mar;18(2):286-94. doi: 10.1017/S135561771100169X. Epub 2011 Dec 15. PubMed 22172155 ↗
  • Forcano L, Soldevila-Domenech N, Boronat A, Sanchez-Benavides G, Puig-Pijoan A, Lorenzo T, Aldea-Perona A, Suarez-Calvet M, Cuenca-Royo A, Gispert JD, Gomis-Gonzalez M, Minguillon C, Diaz-Pellicer P, Fauria K, Piera I, Langohr K, Dierssen M, Pizarro N, Mur-Gimeno E, Grau-Rivera O, Molinuevo JL, de la Torre R; PENSA working group. A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- varepsilon4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study). J Prev Alzheimers Dis. 2025 Sep;12(8):100271. doi: 10.1016/j.tjpad.2025.100271. Epub 2025 Jul 15. PubMed 40664536 ↗
  • Nishi SK, Babio N, Gomez-Martinez C, Martinez-Gonzalez MA, Ros E, Corella D, Castaner O, Martinez JA, Alonso-Gomez AM, Warnberg J, Vioque J, Romaguera D, Lopez-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem JL, Bueno-Cavanillas A, Tur JA, Martin Sanchez V, Pinto X, Delgado-Rodriguez M, Matia-Martin P, Vidal J, Vazquez C, Daimiel L, Razquin C, Coltell O, Becerra-Tomas N, De La Torre Fornell R, Abete I, Sorto-Sanchez C, Baron-Lopez FJ, Signes-Pastor AJ, Konieczna J, Garcia-Rios A, Casas R, Gomez-Perez AM, Santos-Lozano JM, Garcia-Arellano A, Guillem-Saiz P, Ni J, Trinidad Soria-Florido M, Zulet MA, Vaquero-Luna J, Toledo E, Fito M, Salas-Salvado J. Mediterranean, DASH, and MIND Dietary Patterns and Cognitive Function: The 2-Year Longitudinal Changes in an Older Spanish Cohort. Front Aging Neurosci. 2021 Dec 13;13:782067. doi: 10.3389/fnagi.2021.782067. eCollection 2021. PubMed 34966270 ↗
  • Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, Hyman BT, Blacker D, Detoledo-Morrell L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011 Apr 19;76(16):1395-402. doi: 10.1212/WNL.0b013e3182166e96. Epub 2011 Apr 13. PubMed 21490323 ↗
  • Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004 Mar;13(2):299-310. doi: 10.1023/B:QURE.0000018486.91360.00. PubMed 15085902 ↗
  • Ruiz Comellas A, Pera G, Baena Diez JM, Mundet Tuduri X, Alzamora Sas T, Elosua R, Toran Monserrat P, Heras A, Fores Raurell R, Fuste Gamisans M, Fabrega Camprubi M. [Validation of a Spanish Short Version of the Minnesota Leisure Time Physical Activity Questionnaire (VREM)]. Rev Esp Salud Publica. 2012 Oct;86(5):495-508. doi: 10.4321/S1135-57272012000500004. Spanish. PubMed 23223762 ↗
  • Matton A, Stephen R, Daniilidou M, Barbera M, Alanko V, Ballin M, Ford J, Hemio K, Lehtisalo J, Rocha SL, Mangialasche F, Ngandu T, Rosenberg A, Saadmaan G, Udeh-Momoh C, Uusimaki K, Solomon A, Kivipelto M. Mechanisms of interventions targeting modifiable factors for dementia risk reduction. Mol Neurodegener. 2025 Jun 23;20(1):75. doi: 10.1186/s13024-025-00845-w. PubMed 40551205 ↗
  • Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. Curr Drug Targets. 2017;18(2):174-195. doi: 10.2174/1389450116666150825113655. PubMed 26302801 ↗
  • Barbera M, Perera D, Matton A, Mangialasche F, Rosenberg A, Middleton L, Ngandu T, Solomon A, Kivipelto M. Multimodal Precision Prevention - A New Direction in Alzheimer's Disease. J Prev Alzheimers Dis. 2023;10(4):718-728. doi: 10.14283/jpad.2023.114. PubMed 37874092 ↗
  • Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC, Ferri CP, Gitlin LN, Howard R, Kales HC, Kivimaki M, Larson EB, Nakasujja N, Rockwood K, Samus Q, Shirai K, Singh-Manoux A, Schneider LS, Walsh S, Yao Y, Sommerlad A, Mukadam N. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31. No abstract available. PubMed 39096926 ↗
  • Frisoni GB, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, Abramowicz M, Barkhof F, Berthier M, Bieler-Aeschlimann M, Blennow K, Brioschi Guevara A, Carrera E, Chetelat G, Csajka C, Demonet JF, Dodich A, Garibotto V, Georges J, Hurst S, Jessen F, Kivipelto M, Llewellyn DJ, McWhirter L, Milne R, Minguillon C, Miniussi C, Molinuevo JL, Nilsson PM, Noyce A, Ranson JM, Grau-Rivera O, Schott JM, Solomon A, Stephen R, van der Flier W, van Duijn C, Vellas B, Visser LNC, Cummings JL, Scheltens P, Ritchie C, Dubois B. Dementia prevention in memory clinics: recommendations from the European task force for brain health services. Lancet Reg Health Eur. 2023 Jan 31;26:100576. doi: 10.1016/j.lanepe.2022.100576. eCollection 2023 Mar. PubMed 36895446 ↗
  • Sindi S, Nasholm MS, Barbera M, Thunborg C, Li Y, Jonsson L, Mangialasche F, Qiu C, Kivipelto M. From dementia prevention research to global FINGER-based multi-domain interventions and implementation strategies. Cereb Circ Cogn Behav. 2025 May 30;9:100385. doi: 10.1016/j.cccb.2025.100385. eCollection 2025. PubMed 41017958 ↗
  • Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12. PubMed 25771249 ↗
  • Ngandu T, Solomon A, Lehtisalo J, et al. Long-term adherence to lifestyle changes and association with cognitive change: 11-year results from the FINGER randomized, controlled trial. Alzheimers Dement. 2025;21(Suppl 6):e106542. Published 2025 Dec 23. doi:10.1002/alz70860_106542.
  • Forcano L, Fauria K, Soldevila-Domenech N, Minguillon C, Lorenzo T, Cuenca-Royo A, Menezes-Cabral S, Pizarro N, Boronat A, Molinuevo JL, de la Torre R; PENSA Study Groupǂ. Prevention of cognitive decline in subjective cognitive decline APOE epsilon4 carriers after EGCG and a multimodal intervention (PENSA): Study design. Alzheimers Dement (N Y). 2021 Mar 31;7(1):e12155. doi: 10.1002/trc2.12155. eCollection 2021. PubMed 33816762 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 12 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 28, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730671
Lead sponsor
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Collaborators
Hospital del Mar, Hospital del Mar Research Institute (IMIM)
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 28, 2026

Study contacts

Natàlia Soldevila Domènech, MPH, PhD
Contact
nsoldevila@barcelonabeta.org
(+34) 93 316 09 90

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion